Relmada Therapeutics (NASDAQ:RLMD) Issues Quarterly Earnings Results

Relmada Therapeutics (NASDAQ:RLMD) issued its earnings results on Tuesday. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.04), FiscalAI reports.

Here are the key takeaways from Relmada Therapeutics’ conference call:

• Relmada said it remains on track to initiate the phase III RESCUE program for NDV-01 in mid-2026, supported by FDA alignment and a newly completed $160 million private placement.
• The company highlighted strong 12-month phase II NDV-01 data in high-risk NMIBC, including a 95% complete response rate at any time and durable 76% CR at 12 months, with no progression to muscle-invasive disease or radical cystectomy.
• Management emphasized NDV-01’s favorable safety profile and office-friendly delivery, saying it can be administered in under five minutes without a specialized pharmacy, which they believe could support real-world adoption.
• Relmada filed a provisional U.S. patent application for NDV-01 formulations and methods of treatment that, if granted and expanded globally, could extend coverage into 2047 and strengthen commercial exclusivity.
• The company ended Q1 with $234 million in cash and said it expects that runway to fund operations through 2029, including completion of the NDV-01 phase III program, while also preparing a mid-2026 proof-of-concept study for sepranolone in Prader-Willi syndrome.

Relmada Therapeutics Trading Down 1.4%

Relmada Therapeutics stock traded down $0.11 during trading on Thursday, reaching $7.39. The company had a trading volume of 67,133 shares, compared to its average volume of 1,417,299. Relmada Therapeutics has a 52 week low of $0.38 and a 52 week high of $8.00. The firm’s 50-day simple moving average is $6.73 and its 200 day simple moving average is $4.91. The firm has a market capitalization of $774.61 million, a price-to-earnings ratio of -6.77 and a beta of 0.43.

Hedge Funds Weigh In On Relmada Therapeutics

A number of institutional investors have recently bought and sold shares of RLMD. XTX Topco Ltd bought a new position in Relmada Therapeutics in the 2nd quarter worth $28,000. Goldman Sachs Group Inc. bought a new position in Relmada Therapeutics in the 1st quarter worth $33,000. LMR Partners LLP bought a new position in Relmada Therapeutics in the 2nd quarter worth $33,000. Schonfeld Strategic Advisors LLC bought a new position in Relmada Therapeutics in the 4th quarter worth $64,000. Finally, Jane Street Group LLC bought a new position in Relmada Therapeutics in the 2nd quarter worth $69,000. 45.24% of the stock is owned by institutional investors.

Analyst Ratings Changes

RLMD has been the topic of several recent analyst reports. Zacks Research upgraded Relmada Therapeutics to a “hold” rating in a research note on Tuesday, January 27th. Piper Sandler assumed coverage on Relmada Therapeutics in a report on Tuesday, March 24th. They set an “overweight” rating and a $12.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Relmada Therapeutics in a report on Wednesday, January 28th. Mizuho increased their price target on Relmada Therapeutics from $10.00 to $19.00 and gave the company an “outperform” rating in a report on Friday, March 20th. Finally, Lucid Cap Mkts raised Relmada Therapeutics to a “strong-buy” rating in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.